Purpose of Review

Ibrutinib is a first-in-class, highly potent Bruton tyrosine kinase inhibitor which has become standard of care for patients with chronic lymphocytic leukaemia and other lymphoproliferative disorders. It requires indefinite administration which places emphasis on toxicity and long-term tolerance.

Recent Findings

Extensive use of ibrutinib in studies and clinical practice has better defined its full toxicity profile which has made its use more challenging than initially foreseen. In particular, dysrhythmias, bleeding, infections and constitutional symptoms have been reported and can result in dose reduction or discontinuation of ibrutinib.

Summary

Herein, we review the common as well as rare but important toxicities and discuss approach and management on a practical level. We also highlight that patients should be regularly monitored for adverse events and proactively treated to minimise side effects and avoid disruption.

中文翻译：

---

依鲁替尼毒性的管理：实用指南。

审查目的

依鲁替尼（Ibrutinib）是一流的，高效的Bruton酪氨酸激酶抑制剂，已成为慢性淋巴细胞性白血病和其他淋巴增生性疾病患者的治疗标准。它需要无限期给药，重点放在毒性和长期耐受性上。

最近的发现

在研究和临床实践中广泛使用依鲁替尼已更好地定义了其全部毒性特征，这使它的使用比最初预见的更具挑战性。特别是，据报道有心律不齐，出血，感染和体质症状，并可能导致依鲁替尼剂量减少或停药。

概要

在此，我们回顾了常见的，罕见的但重要的毒性，并在实践水平上讨论了方法和管理。我们还强调，应定期监测患者的不良事件并积极治疗，以最大程度地减少副作用并避免干扰。